Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Change in Accured Expenses rose 39195.09% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 52197.86%. This contributed to the annual value of $1.5 million for FY2024, which is 12069.06% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Change in Accured Expenses is $3.6 million, which was up 39195.09% from $3.2 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Change in Accured Expenses high stood at $4.4 million for Q4 2022, and its period low was -$17.3 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$791000.0 (2022), whereas its average is -$2.7 million.
  • As far as peak fluctuations go, Theravance Biopharma's Change in Accured Expenses crashed by 42998.33% in 2021, and later skyrocketed by 78287.67% in 2024.
  • Over the past 5 years, Theravance Biopharma's Change in Accured Expenses (Quarter) stood at -$652000.0 in 2021, then soared by 771.63% to $4.4 million in 2022, then tumbled by 110.0% to -$438000.0 in 2023, then skyrocketed by 782.88% to $3.0 million in 2024, then rose by 20.56% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.2 million for Q2 2025, and -$1.5 million during Q1 2025.